BPC-157

What BPC-157 is

BPC-157 (short for Body Protection Compound-157) is a synthetic 15-amino-acid peptide, a pentadecapeptide originally isolated from human gastric juice. Predrag Sikiric's research group first described it in the early 1990s, and a large share of the animal research since then has come from that same group.

It's sold online as a research chemical and is one of the most-discussed peptides among lifters and other athletes with soft-tissue injuries.

The short version: rodent studies are consistent and mostly positive, while human data amount to three small uncontrolled pilot studies. On this site's scale that's emerging evidence. It's enough to take seriously as a research question, but not enough to know whether BPC-157 works or is safe in people.

How it seems to work

Nearly everything known about the mechanism comes from rats and cell cultures, which point to several overlapping pathways:

Angiogenesis: more VEGF expression and VEGFR2 activity, which could matter in tissue with a poor blood supply, such as tendon.
Nitric oxide signaling: upregulation of nitric oxide synthase and higher nitric oxide production.
Cell migration and growth: in cultured rat tendon cells, more FAK-paxillin activity and more growth hormone receptor expression.
Inflammation: lower IL-6, TNF-alpha and COX-2 in injury models.
Brain chemistry: shifts in dopamine and serotonin signaling in rat studies.

Its half-life is under 30 minutes in rat and dog studies, yet effects in animals lasted for weeks. Reviewers suggest it switches on gene programs that keep running after the peptide is gone. Nobody has measured that in people.

What the evidence shows

Animal studies

A 2025 systematic review in HSS Journal kept 36 studies relevant to sports medicine, and 35 were preclinical. In rats, BPC-157 improved the structure and strength of cut Achilles and quadriceps tendons. It also helped injured muscle and a cut knee ligament (the MCL) recover. In a rabbit study, it healed a bone defect about as well as a bone graft did.

Gut research goes back further, including 1990s rat studies of stomach damage caused by NSAIDs. When FDA's advisory committee reviewed BPC-157 in July 2026, the use it evaluated was ulcerative colitis.

Two caveats apply. A 2025 narrative review pointed out that every published study reports a benefit, which raises the possibility of publication bias. Doses and routes in these studies also differ from how people use the peptide.

Human studies

As of October 2026, no controlled human trial of BPC-157 has published results. Three small pilot studies exist, all led by the same first author and none with a control group:

Knee pain (2021): a retrospective look at 16 patients who had knee injections of BPC-157, alone or with thymosin beta-4. Fourteen reported relief; of the 12 who got BPC-157 alone, 7 said it lasted more than six months.
Interstitial cystitis (2024): 12 patients received BPC-157 directly into the bladder. All 12 rated themselves significantly improved at six weeks.
IV safety (2025): two adults received 10 mg, then 20 mg the next day, by one-hour intravenous infusion. Neither reported side effects, and heart, liver, kidney, thyroid and glucose markers didn't change.

An oral Phase 1 trial of 1 mg tablets (PCO-02), registered in 2015, is listed with unknown status and never posted results. A newer University of Arkansas pilot plans to compare daily subcutaneous injections for 90 days after rotator cuff surgery against placebo or no treatment. As of October 2026 it isn't recruiting yet; the listed start date is January 2027.

What users report

Forum reports are less consistent than the lab data. On peptide forums, the commonly cited range is 250-500 mcg per day by subcutaneous injection, sometimes split into two doses. Some users describe a loading phase of 500 mcg twice daily (1 mg per day) for the first two weeks after an acute injury, then dropping back. In one 2026 PepAtlas thread, a user who tried both approaches on similar injuries said the recovery timelines felt the same, and noted that physical therapy or placebo could explain the improvement.

Many people inject near the injured area. No study supports or rules out that practice. The animal studies used systemic routes such as intraperitoneal injection or oral dosing and still reported effects in tendon and muscle. No human study has compared injection sites.

Some forum posts scale rodent data up to claim the benefit plateaus around 2 mg per day in people. That's a conversion, not a tested human dose.

Vendor guidance, including this site's product listing, typically gives 4-12 weeks. No study has tested any duration in people; rodent studies ran from a single dose to 90 days of daily dosing.

Many users combine BPC-157 with TB-500. Beyond the knee series above, we found no study of the combination.

Side effects and safety

Human safety data are minimal. The 2025 systematic review found no clinical safety data in the literature through mid-2024. The three pilots reported no adverse effects, but they included 30 people in total and weren't designed to catch uncommon problems.

Studies in rats and dogs found no toxic or lethal dose anywhere from 6 mcg/kg to 20 mg/kg, and standard tests found no genotoxicity or birth defects. None of these studies followed animals for longer than six weeks.

User reports are broader. The systematic review notes that anonymous online users describe:

injection-site pain and swelling
joint pain
anxiety, panic attacks and heart palpitations
insomnia or drowsiness
weakness, fatigue and loss of appetite
low mood and anhedonia (loss of pleasure)

Vendor and community summaries also mention nausea, dizziness and headache; we couldn't trace those to a study. As the review's authors note, online reports can't separate BPC-157 from contaminated or mislabeled products.

Because BPC-157 promotes angiogenesis, some reviewers raise a theoretical risk of feeding tumor growth. So far the animal data point the other way, with some studies finding it suppressed VEGF-driven tumor growth. Nobody has studied this in people over the long term.

Is BPC-157 legal?

As of October 2026, no regulator has approved BPC-157 as a medicine.

In the US, FDA put BPC-157 in Category 2 of its compounding framework in 2023, the group of substances that may pose significant safety risks. FDA cited possible immune reactions and peptide-related impurities, with little safety information to go on. On April 15, 2026, FDA announced that BPC-157 and 11 other peptides would come off Category 2 because their nominations had been withdrawn. Removal didn't make them legal to compound; they now sit in no category.

At its July 23-24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8-6-1 to recommend adding BPC-157 to the 503A bulks list, even though FDA staff had recommended against it. The same day it backed KPV, an anti-inflammatory tripeptide, and TB-500 by the same margin, and the mitochondrial peptide MOTS-c 7-5-2. The votes are advisory. Only a final FDA rule would let licensed pharmacies compound BPC-157 for individual prescriptions, and as of October 2026 we found no proposed rule. A second meeting, planned before the end of February 2027, is set to cover five more peptides, including the copper peptide GHK-Cu and the antimicrobial peptide LL-37.

None of this changes the status of research-use-only sales. Compounding rules cover licensed pharmacies filling prescriptions, and a research-chemical label doesn't make selling or using BPC-157 in people lawful.

For athletes, WADA has named BPC-157 in class S0 (non-approved substances) since its 2022 list. The 2026 Prohibited List keeps it there, so it's banned both in and out of competition. Lab methods can detect its metabolites in urine for about four to five days after use.

Product quality

Because BPC-157 isn't an approved drug, no regulator checks what's in a vial sold under that name. That matters when reading user reports, since a bad vial can explain both a missing benefit and an unexpected side effect. Vendors publish certificates of analysis, but those are the seller's own claims.

What we still don't know

Whether the tendon, muscle and gut effects seen in rats carry over to people. The Arkansas rotator cuff pilot, if it starts in 2027 as planned, would be the first controlled test.
Whether dose, route or injection site makes any difference. No human dose-finding study exists.
Long-term safety. No animal study ran past six weeks, and the human pilots together covered 30 people.